Ustekinumab 90mg Injection

Ustekinumab 90mg Injection is a prescription biologic medicine containing ustekinumab, a human monoclonal antibody that selectively targets interleukin-12 (IL-12) and interleukin-23 (IL-23). It is used for the treatment of certain immune-mediated inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, depending on the approved indication.

Ustekirel 90mg is a brand of ustekinumab manufactured by Reliance Life Sciences. It is positioned as a generic/biosimilar alternative to Stelara® where approved and available.

Product Information

Generic Name

Ustekinumab 90mg

Brand Name

Ustekirel 90mg

Reference Brand

Stelara®

Manufacturer

Reliance Life Sciences

Drug Class

Biologic / IL-12 and IL-23 Inhibitor

Indications

Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis

Form

Injection

Strength

90mg

Route

Subcutaneous Injection

Prescription

Yes

Active Ingredient

Ustekinumab

Packing

Manufacturer Dependent

Generic Stelara® / Ustekirel 90mg

Stelara® is the reference brand of ustekinumab. Ustekirel 90mg, manufactured by Reliance Life Sciences, contains ustekinumab and may be marketed as a biosimilar or alternative to the reference product depending on the applicable regulatory approval.

For SEO and product naming, the strongest primary name is:

Ustekinumab 90mg Injection

Use Ustekirel 90mg and Generic Stelara® as secondary keyword/description terms.

Availability & Ordering

Patients searching for Ustekinumab 90mg Injection, Ustekirel 90mg, Generic Stelara®, Ustekinumab 90mg Price, Ustekinumab for Psoriasis, Ustekinumab for Psoriatic Arthritis, Ustekinumab for Crohn's Disease, Ustekinumab for Ulcerative Colitis, and Ustekinumab Biologic Injection can find prescription products through licensed pharmaceutical suppliers, subject to local prescription and regulatory requirements.

How it works

Ustekinumab is a monoclonal antibody that binds to the p40 protein subunit shared by IL-12 and IL-23. Blocking these cytokine pathways helps reduce inflammatory immune responses involved in several chronic inflammatory diseases.

Ustekinumab 90mg may be prescribed for eligible patients with:

• Moderate-to-severe plaque psoriasis
• Active psoriatic arthritis
• Moderately to severely active Crohn's disease
• Moderately to severely active ulcerative colitis

The approved indications and dosing schedules may vary according to country, patient age, and medical condition.